Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
Abstract: Accurate measurement of clotting factors VIII (FVIII) or IX (FIX) is vital for comprehensive diagnosis and management of patients with hemophilia A or B. The one-stage activated partial thromboplastin time (aPTT)-based clotting assay is the most commonly used method worldwide for testing FVIII or FIX activities. Alternatively, FVIII and FIX chromogenic substrate assays, which assess the activation of factor X, are available in some specialized laboratories. The choice of reagent or methodology can strongly influence the resulting activity. Variation between one-stage FVIII or FIX activities has been reported in the measurement of some standard and extended half-life factor replacement therapies and gene therapy for hemophilia B using different aPTT reagents. Discrepancy between one-stage and chromogenic reagents has been demonstrated in some patients with mild hemophilia A or B, the measurement of some standard and extended half-life factor replacement therapies, and the transgene expression of hemophilia A and B patients who have received gene therapy. Finally, the measurement of bispecific antibody therapy in patients with hemophilia A has highlighted differences between chromogenic assays. It is imperative that hemostasis laboratories evaluate how suitable their routine assays are for the accurate measurement of the various hemophilia treatment therapies.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments ; day:06 ; month:12 ; year:2022
Seminars in thrombosis and hemostasis ; (06.12.2022)
- Contributor
-
Bowyer, Annette E.
Gosselin, Robert C.
- DOI
-
10.1055/s-0042-1758870
- URN
-
urn:nbn:de:101:1-2023011914124188040328
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:22 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bowyer, Annette E.
- Gosselin, Robert C.
Other Objects (12)
Factor VIII (FVIII) Antibodies in Hemophilia
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre
Oral Prophylactic Therapy in Hemophilia A and B (Factor VIII and IX Deficiencies)
Isolation and Properties of the Abnormal Factor IX Molecule of Hemophilia BM
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy
Prognostic factors and medical treatments of patients with melanoma
Risk factors and treatments for disseminated intravascular coagulation in neonates
Dropout of infertility treatments and related factors among infertile couples
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
Factor VIII (FVIII) Antibodies in Hemophilia
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre
Oral Prophylactic Therapy in Hemophilia A and B (Factor VIII and IX Deficiencies)
Isolation and Properties of the Abnormal Factor IX Molecule of Hemophilia BM
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy
Prognostic factors and medical treatments of patients with melanoma
Risk factors and treatments for disseminated intravascular coagulation in neonates
Dropout of infertility treatments and related factors among infertile couples
Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A
Factor VIII (FVIII) Antibodies in Hemophilia
Population Pharmacokinetics of Clotting Factor Concentrates and Desmopressin in Hemophilia
Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management
Health-related quality of life and its associated factors among hemophilia patients: experience from Ethiopian Hemophilia Treatment Centre
Oral Prophylactic Therapy in Hemophilia A and B (Factor VIII and IX Deficiencies)
Isolation and Properties of the Abnormal Factor IX Molecule of Hemophilia BM
Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy
Prognostic factors and medical treatments of patients with melanoma
Risk factors and treatments for disseminated intravascular coagulation in neonates
Dropout of infertility treatments and related factors among infertile couples